Denali Therapeutics Stock Price and Value Analysis

Should you buy Denali Therapeutics stock? (NASDAQ:DNLI). Let's see how it does in our automated value investing analysis system.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Denali Therapeutics to reach your target.

Target type

DNLI Free Cash Flow Trend

Free Cash Flow trendline for DNLI
Free Cash Flow trendline for Denali Therapeutics

Hmm, we can't give any reliable projection for Denali Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company is not making money.
  • This company is less known than others.
  • This company pays no dividend.

Inside the DNLI Numbers

DNLI Price
(Denali Therapeutics stock price per share)
$23.11
[?] PE Ratio versus Sector 191% higher than other Healthcare stocks
[?] PE Ratio versus Industry 2% higher than other Biotechnology stocks
[?] Free Cash Flow Jitter 51%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 16,035,916 shares shorted. With 144,219,538 shares available for purchase and an average trading volume over the past 10 trading days of 1,956,520, it would take at least 8.196 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Is Denali Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Denali Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Advertisement supports free stock analysis content.

Should You Buy DNLI Stock?

Does Denali Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: DNLI

This example shows how we apply the Trendshare checklist to DNLI: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 23.11
    • Market cap: $3.7B
    • EPS: -2.88
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Jul 28, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.